W

hen Biogen received regulatory approval last month to sell the Spinraza rare disease drug, the company surprised Wall Street by setting a price that few expected — $750,000 for the first year of treatment and $375,000 each year thereafter. At the time, at least one analyst suggested the price tag amounted to “sticker shock” that may cheer investors, but also invite criticism amid growing outrage over drug pricing.

Already, the scrutiny has begun.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X